Condition
Healthy Participant Study
Total Trials
5
Recruiting
3
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 1 (3)
Trial Status
Recruiting3
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07572513Not ApplicableRecruiting
Slowly Digestible Carbohydrates for GLP-1 Secretion
NCT07421778Phase 1RecruitingPrimary
A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants
NCT07406464Not ApplicableCompletedPrimary
MRI-tDCS Criticism Study
NCT07304791Phase 1Recruiting
This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects
NCT07146191Phase 1CompletedPrimary
RE104 Radiolabeled Mass Balance (hAME) Study
Showing all 5 trials